Humacyte is trading 5.26% up now at $0.68 after announcing on August 24, 2026, that FDA discussions confirmed plans to file a supplemental BLA for ATEV dialysis access in November.
- The filing would seek a second approved indication after vascular-trauma approval.
- Trading volume and activity-level data were unavailable.